BR112018015238A2 - conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição - Google Patents

conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição

Info

Publication number
BR112018015238A2
BR112018015238A2 BR112018015238A BR112018015238A BR112018015238A2 BR 112018015238 A2 BR112018015238 A2 BR 112018015238A2 BR 112018015238 A BR112018015238 A BR 112018015238A BR 112018015238 A BR112018015238 A BR 112018015238A BR 112018015238 A2 BR112018015238 A2 BR 112018015238A2
Authority
BR
Brazil
Prior art keywords
disease
condition
antibody
methods
diagnosing
Prior art date
Application number
BR112018015238A
Other languages
English (en)
Inventor
Sato Aaron
Yam Alice
Gill Avinash
Penta Kalyani
stafford Ryan
Li Xiaofan
Original Assignee
Sutro Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma Inc filed Critical Sutro Biopharma Inc
Publication of BR112018015238A2 publication Critical patent/BR112018015238A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

são providos aqui conjugados de anticorpo com especificidade aglutinante para cd74, em que o anticorpo compreende um aminoácido não natural em um local selecionado a partir do grupo que consiste em hc-f404, hc-k121, hc-y180, hc-f241, hc-221, lc-t22, lc-s7, lc-n152, lc-k42, lc-e161, lc-d170, hc-s136, hc-s25, hc-a40, hc-s119, hc-s190, hc-k222, hc-r19, hc-y52, ou hc-s70 de acordo com o sistema numérico kabat, chothia ou europeu, e composições compreendendo os conjugados de anticorpo, incluindo composições farmacêuticas, métodos para produção dos conjugados e métodos para uso dos conjugados e composições para terapia.
BR112018015238A 2016-01-27 2017-01-27 conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição BR112018015238A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662287824P 2016-01-27 2016-01-27
PCT/US2017/015501 WO2017132615A1 (en) 2016-01-27 2017-01-27 Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates

Publications (1)

Publication Number Publication Date
BR112018015238A2 true BR112018015238A2 (pt) 2018-12-18

Family

ID=58018253

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015238A BR112018015238A2 (pt) 2016-01-27 2017-01-27 conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição

Country Status (14)

Country Link
US (1) US11708413B2 (pt)
EP (1) EP3407917A1 (pt)
JP (2) JP7306827B2 (pt)
KR (1) KR20180104106A (pt)
CN (2) CN114796520A (pt)
AU (1) AU2017212739B2 (pt)
BR (1) BR112018015238A2 (pt)
CA (1) CA3011455A1 (pt)
IL (1) IL260586B2 (pt)
MX (1) MX2018009085A (pt)
RU (1) RU2018130757A (pt)
SG (1) SG11201806419RA (pt)
WO (2) WO2017132617A1 (pt)
ZA (1) ZA201804654B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
KR20180104106A (ko) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
US20200353076A1 (en) * 2017-09-18 2020-11-12 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugates and their uses
US20220047716A1 (en) * 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
EP3962951A1 (en) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
AU2020270407A1 (en) 2019-05-03 2021-12-02 Celgene Corporation Anti-BCMA antibody conjugate, compositions comprising the same, and methods of making and using the same
CN114269749A (zh) 2019-06-10 2022-04-01 苏特罗生物制药公司 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
US11744876B2 (en) * 2019-06-10 2023-09-05 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
JP2022536800A (ja) 2019-06-17 2022-08-18 ストロ バイオファーマ インコーポレーテッド Ｔｏｌｌ様受容体（ｔｌｒ）７／８アゴニストとしての１－（４－（アミノメチル）ベンジル）－２－ブチル－２ｈ－ピラゾロ［３，４－ｃ］キノリン－４－アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
KR20230004682A (ko) 2020-04-22 2023-01-06 머크 샤프 앤드 돔 엘엘씨 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Coupling materials with triple specificity
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
WO2023192993A2 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Antibodies against human siglec-7 and use thereof for immunotherapy
CN116139267A (zh) * 2023-01-28 2023-05-23 华中科技大学同济医学院附属同济医院 小鼠cd74单克隆抗体在制备***药物中的应用

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5869644A (en) 1992-04-15 1999-02-09 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotidies
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HUP9903014A3 (en) 1996-07-18 2000-08-28 Pfizer Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
US6153609A (en) 1996-08-23 2000-11-28 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CA2277100C (en) 1997-01-06 2005-11-22 Pfizer Inc. Cyclic sulfone derivatives
TR199901849T2 (xx) 1997-02-03 2000-02-21 Pfizer Products Inc. Arils�lfonilamino hidroksamik asit t�revleri.
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
ATE359515T1 (de) 1997-02-12 2007-05-15 Electrophoretics Ltd Proteinmarker für lungenkrebs und deren verwendung
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
ATE263147T1 (de) 1997-08-08 2004-04-15 Pfizer Prod Inc Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
ATE279430T1 (de) 1998-03-05 2004-10-15 Chiron Corp Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
ATE321066T1 (de) 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
CA2399358C (en) 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
JP4860098B2 (ja) 2000-12-18 2012-01-25 ダイアックス、コープ 遺伝的パッケージの焦点を合わせたライブラリー
JP2005502322A (ja) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7026440B2 (en) 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA2496437C (en) 2002-08-19 2013-01-08 The Board Of Trustees Of The Leland Stanford Junior University Improved methods of in vitro protein synthesis
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
EP1682584B1 (en) 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP2380982B1 (en) 2004-10-27 2014-07-16 The Scripps Research Institute Orthogonal translation components for the in vivo incorporation of unnatural amino acids
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
JP5425398B2 (ja) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
DK1968635T3 (en) 2005-12-14 2014-12-15 Ambrx Inc Compositions and Methods of, and uses of non-natural amino acids and polypeptides
EP1974025A4 (en) 2006-01-19 2009-03-11 Ambrx Inc NON-NATURAL AMINO ACID POLYPEPTIDES WITH MODULATED IMMUNOGENICITY
EP2395099A3 (en) 2006-05-02 2012-05-16 Allozyne, Inc. Amino acid substituted molecules
JP5620100B2 (ja) 2006-06-29 2014-11-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 非天然アミノ酸を含有するタンパク質の無細胞合成の方法
EP2064316B1 (en) 2006-09-08 2012-01-25 Ambrx, Inc. Site specific incorporation of non-natural amino acids by vertebrate cells
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
WO2008083346A1 (en) 2006-12-28 2008-07-10 Ambrx, Inc. Phenazine and quinoxaline substituted amino acids and polypeptides
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
EP2193146B1 (en) 2007-09-14 2016-05-25 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
WO2010051056A2 (en) 2008-03-11 2010-05-06 Ambrx, Inc. ANTI-FcεRI POLYPEPTIDES AND THEIR USES
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
EP2389192A4 (en) 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
GB2470770A (en) 2009-06-04 2010-12-08 Medical Res Council Incorporation of unnatural amino acids having an orthogonal functional group into polypeptides using orthogonal tRNA/tRNA synthetase pairs
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
CN103153927B (zh) 2010-04-27 2017-02-15 西纳福克斯股份有限公司 稠合的环辛炔化合物及其在无金属点击反应中的应用
JP6173911B2 (ja) 2010-09-10 2017-08-09 メディミューン リミテド 抗体誘導体
EP2648748A1 (en) * 2010-12-08 2013-10-16 Stem Centrx, Inc. Novel modulators and methods of use
SG10201608138RA (en) 2011-02-01 2016-11-29 Genmab As Human antibodies and antibody-drug conjugates against cd74
WO2012134925A1 (en) 2011-03-25 2012-10-04 Life Technologies Corporation Heterobifunctional esters for use in labeling target molecules
US20130251783A1 (en) 2011-09-14 2013-09-26 Universitat Heidelberg Liposomes containing permeation enhancers for oral drug delivery
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
WO2013092983A2 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
CN102627615B (zh) 2012-03-23 2014-01-01 兰州大学 一种化合物l-4-四嗪-苯丙氨酸及其制备方法和应用
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
ES2907763T3 (es) 2012-08-31 2022-04-26 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
CN105026574B (zh) 2012-09-24 2019-08-30 米迪缪尼有限公司 细胞系
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
ES2730011T3 (es) 2013-02-20 2019-11-07 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
ES2658039T3 (es) * 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
ES2753551T3 (es) 2014-07-22 2020-04-13 Sutro Biopharma Inc Anticuerpos anti-cd74, composiciones que comprenden anticuerpos anti-CD74 y procedimientos de uso de los anticuerpos anti-CD74
RS60631B1 (sr) * 2014-11-21 2020-09-30 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
PL3250237T3 (pl) * 2015-01-30 2021-12-13 Sutro Biopharma, Inc. Pochodne hemiasterliny do koniugacji i terapii
CN106146663B (zh) * 2015-04-10 2019-11-08 北京大学 非天然氨基酸标记的新型抗体-药物偶联物及其制备
KR20180104106A (ko) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
US20200009262A1 (en) 2016-05-13 2020-01-09 Tarveda Therapeutics, Inc. Targeted constructs and formulations thereof
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA

Also Published As

Publication number Publication date
JP7306827B2 (ja) 2023-07-11
IL260586A (en) 2022-12-01
JP2022027823A (ja) 2022-02-14
CN114796520A (zh) 2022-07-29
CA3011455A1 (en) 2017-08-03
EP3407917A1 (en) 2018-12-05
US20190144546A1 (en) 2019-05-16
MX2018009085A (es) 2019-05-09
SG11201806419RA (en) 2018-08-30
AU2017212739A1 (en) 2018-07-26
IL260586B2 (en) 2023-04-01
CN109069664A (zh) 2018-12-21
ZA201804654B (en) 2024-01-31
RU2018130757A3 (pt) 2020-07-17
WO2017132617A1 (en) 2017-08-03
CN109069664B (zh) 2022-05-13
US11708413B2 (en) 2023-07-25
RU2018130757A (ru) 2020-02-27
KR20180104106A (ko) 2018-09-19
AU2017212739B2 (en) 2024-03-21
JP2019506385A (ja) 2019-03-07
WO2017132615A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
BR112017002080A2 (pt) ?anticorpo monoclonal ou fragmento de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para preparar o anticorpo monoclonal ou fragmento de ligação, in vivo ou in vitro e para prevenção e/ou tratamento e/ou terapia adjuvante e/ou diagnóstico de um tumor, conjugado, kit, uso de um anticorpo monoclonal ou fragmento de ligação, e, composição farmacêutica?
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112021023229A2 (pt) Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
BR112017013661A2 (pt) conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112018013407A2 (pt) anticorpos e conjugados dos mesmos
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BRPI0622054B8 (pt) composto e composição farmacêutica
BR112015014751A2 (pt) anticorpos anti-tau humanos
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BR112017014771A2 (pt) ?anticorpo, polinucleotídeo, unidade de expressão, célula hospedeira, métodos para produção de um anticorpo e para tratamento de um indivíduo, composição, uso de um anticorpo em um método de diagnóstico, e, vetor de expressão?
BRPI0905733B8 (pt) composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
CY1117118T1 (el) Φαρμακευτικος συνδυασμος για την αγωγη του πονου
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]